

Press Release – For immediate release

## **BIOLIDICS ENTERS INTO ANOTHER PARTNERSHIP IN CHINA TO DEVELOP NEW COMMERCIAL APPLICATIONS USING BIOLIDICS' CLEARCELL® FX1 SYSTEM AND CTCHIP® FR1 BIOCHIPS**

- **Partnership with Genecast Biotechnology which specialises in oncology testing and diagnostics for cancer diagnosis, tumor profiling and monitoring in the People's Republic of China ("PRC")**
- **Both parties will collaborate to develop and market laboratory-developed tests ("LDTs") in the field of circulating tumor cells ("CTCs") based on Biolidics' technology**
- **Further validation of Biolidics' unique and position as an upstream technology within the cancer diagnostic value-chain in the field of liquid biopsy**
- **New channel to potentially increase the sales of Biolidics' ClearCell® FX1 System and CTChip® FR1 biochips in the PRC**

**Singapore, 14 May 2019 – Biolidics Limited ("Biolidics" or the "Company"),** a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce that it has entered into a partnership with Genecast Biotechnology Co., Ltd. ("Genecast Biotechnology") (臻和(北京)科技有限公司) to develop new commercial applications in the PRC using Biolidics' ClearCell® FX1 System and CTChip® FR1 biochips.

As an upstream technology within the cancer diagnostic value-chain in the field of liquid biopsy, the ClearCell® FX1 System has the potential, when coupled with other downstream analytical tests, to serve as a platform technology for the diagnosis, prognosis, treatment selection and treatment monitoring of various types of cancers, through the development of a wide range of clinical or LDTs.

Based in Beijing, Genecast Biotechnology focuses on next generation sequencing technology and bioinformatics in oncology testing and diagnostics for cancer diagnosis, tumor profiling and monitoring.

Genecast Biotechnology has attracted more than US\$65 million of venture capital funding since December 2014, with Matrix Partner China and Loyal Valley Capital as its Series C lead investors. It has established several partnerships and collaborations with many globally reputable medical institutions, life sciences, biotech and pharmaceutical companies to develop in vitro diagnostic device ("IVD") and companion diagnostic tests.

With more than 400 employees (more than 20% having a doctorate degree) and a nationwide sales network, Genecast Biotechnology also has a laboratory, accredited by the prestigious College of American Pathologists ("CAP") and ISO 15189 certified, dedicated to the molecular biology medical tests for cancer patients.

Under the partnership agreement, Biolidics will provide the ClearCell® FX1 System, CTChip® FR1 biochips and other ancillary materials and consumables, as well as installation and training to Genecast Biotechnology and assist in the development of LDTs in the field of CTCs based on Biolidics' technology.

This partnership is Biolidics' third partnership in the PRC. It has previously entered into agreements with Hunan Agen Medicine Laboratory Technology Co., Ltd. ("Hunan Agen Lab") and Holistic Integrative Pharmacy Institute, Hangzhou Normal University for similar commercial application objectives.

It is worth noting that Hunan Agen Lab has recently started to offer LDTs (related to CTCs) as clinical services to cancer patients in Hunan Province.

**Mr. Ivan Lew (廖光品), Executive Director and CEO of Biolidics, said:** *"By combining our novel, patented technology with Genecast Biotechnology's focus on cancer diagnostics and precision medicine in the PRC, we are working together to develop exciting clinical innovations to provide more sophisticated, healthcare solutions to benefit a greater number of cancer patients."*

*"This partnership will be one of our strategic initiatives to unlock the full potential of our liquid biopsy technology and generate industry-leading diagnostic services for cancer patients in the PRC."*

- END -

## **About Biolidics Limited**

(Bloomberg Code: BLD:Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumor cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the CTCs in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration (for the MGI EasyCell System).

For additional information, please visit [www.biolidics.com](http://www.biolidics.com).

***Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.***

**Media & Investor Contacts:**



Mr. Alex TAN  
Mobile: +65 9451 5252  
Email: [alex.tan@8prasia.com](mailto:alex.tan@8prasia.com)

*This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*